Novavax

NOVAVAX INC

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Independent,Presidential,Candidate,Robert,F.,Kennedy,Jr.,Announced,'no,Spoiler'

MRNA

NVAX

El Departamento de Salud de EE. UU. bajo RFK Jr. cancela contratos mRNA y apuesta por vacunas de virus completo y plataformas innovadoras.

HHS cancela 22 proyectos de vacunas mRNA por 500 millones de dólares

Novavax Vaccine

Acciones de Novavax se impulsan tras supera ingresos estimados y eleva previsión anual tras acuerdo con Sanofi por vacuna Nuvaxovid.

Acciones de Novavax suben previsiones tras cerrar acuerdo con Sanofi por Nuvaxovid

News

Las acciones de Novavax caen tras las pérdidas de Moderna y la baja demanda de vacunas COVID. El mercado espera los resultados de NVAX.

Acciones de Novavax caen tras los malos resultados de Moderna y el desplome de la demanda de vacunas

Novavax Inc

Press Releases

Novavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan

Novavax to Participate in BofA Securities 2025 Health Care Conference

Earnings

Novavax Reports First Quarter 2025 Financial Results and Operational Highlights

U.S. FDA Approves BLA for Novavax's COVID-19 Vaccine

Novavax to Participate in Upcoming Investor Conferences

Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial

Novavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study

Novavax to Report Second Quarter 2025 Financial Results on August 6, 2025

Novavax Reports Second Quarter 2025 Financial Results and Operational Highlights

Offerings

Novavax Announces Convertible Debt Refinancing

Ardelyx

Biohaven

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

CureVac

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

89bio

GRAIL

Janux Therapeutics

MiMedx Group

MannKind

NuCana

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Precigen

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Arcus Biosciences

Sionna Therapeutics

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

ARS Pharmaceuticals

Stoke Therapeutics

Spyre Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

B of A Securities

Citigroup

JP Morgan

HC Wainwright & Co.

Jefferies

Comments

Novavax

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL